These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23689905)

  • 41. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. De novo C3 glomerulonephritis in a renal allograft.
    Nahm JH; Song SH; Kim YS; Cheong HI; Lim BJ; Kim BS; Jeong HJ
    Ultrastruct Pathol; 2016; 40(2):112-5. PubMed ID: 26986539
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
    Hawfield A; Iskandar SS; Smith RJ
    Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.
    Zand L; Lorenz EC; Cosio FG; Fervenza FC; Nasr SH; Gandhi MJ; Smith RJ; Sethi S
    J Am Soc Nephrol; 2014 May; 25(5):1110-7. PubMed ID: 24357668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
    Xiao X; Pickering MC; Smith RJ
    Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
    Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
    [TBL] [Abstract][Full Text] [Related]  

  • 47. C3 Glomerulopathy: Pathogenesis and Treatment.
    Ahmad SB; Bomback AS
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. C3 glomerulopathy: A new complement-based entity.
    de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
    Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.
    Madden B; Singh RD; Haas M; Palma LMP; Sharma A; Vargas MJ; Gross L; Negron V; Nate T; Charlesworth MC; Theis JD; Nasr SH; Nath KA; Fervenza FC; Sethi S
    Kidney Int; 2024 May; 105(5):1077-1087. PubMed ID: 38447879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
    Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
    Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
    Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
    Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study.
    Welte T; Arnold F; Westermann L; Rottmann FA; Hug MJ; Neumann-Haefelin E; Ganner A
    BMC Nephrol; 2023 Jan; 24(1):8. PubMed ID: 36631797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
    Von Visger J; Cassol C; Nori U; Franco-Ahumada G; Nadasdy T; Satoskar AA
    BMC Nephrol; 2019 Feb; 20(1):53. PubMed ID: 30764798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eculizumab in dense-deposit disease after renal transplantation.
    Sánchez-Moreno A; De la Cerda F; Cabrera R; Fijo J; López-Trascasa M; Bedoya R; Rodríguez de Córdoba S; Ybot-González P
    Pediatr Nephrol; 2014 Oct; 29(10):2055-9. PubMed ID: 24908321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
    Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
    Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
    Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.